Literature DB >> 33504762

IDH1 mutations induce organelle defects via dysregulated phospholipids.

Adrian Lita1, Artem Pliss2, Andrey Kuzmin2,3, Tomohiro Yamasaki1, Lumin Zhang1, Tyrone Dowdy1, Christina Burks4, Natalia de Val4,5,6, Orieta Celiku1, Victor Ruiz-Rodado1, Elena-Raluca Nicoli7, Michael Kruhlak8, Thorkell Andresson9, Sudipto Das9, Chunzhang Yang1, Rebecca Schmitt2, Christel Herold-Mende10, Mark R Gilbert1, Paras N Prasad2,3, Mioara Larion11.   

Abstract

Infiltrating gliomas are devastating and incurable tumors. Amongst all gliomas, those harboring a mutation in isocitrate dehydrogenase 1 mutation (IDH1mut) acquire a different tumor biology and clinical manifestation from those that are IDH1WT. Understanding the unique metabolic profile reprogrammed by IDH1 mutation has the potential to identify new molecular targets for glioma therapy. Herein, we uncover increased monounsaturated fatty acids (MUFA) and their phospholipids in endoplasmic reticulum (ER), generated by IDH1 mutation, that are responsible for Golgi and ER dilation. We demonstrate a direct link between the IDH1 mutation and this organelle morphology via D-2HG-induced stearyl-CoA desaturase (SCD) overexpression, the rate-limiting enzyme in MUFA biosynthesis. Inhibition of IDH1 mutation or SCD silencing restores ER and Golgi morphology, while D-2HG and oleic acid induces morphological defects in these organelles. Moreover, addition of oleic acid, which tilts the balance towards elevated levels of MUFA, produces IDH1mut-specific cellular apoptosis. Collectively, these results suggest that IDH1mut-induced SCD overexpression can rearrange the distribution of lipids in the organelles of glioma cells, providing new insight into the link between lipid metabolism and organelle morphology in these cells, with potential and unique therapeutic implications.

Entities:  

Year:  2021        PMID: 33504762      PMCID: PMC7840755          DOI: 10.1038/s41467-020-20752-6

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  40 in total

1.  Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.

Authors:  Catherine H Han; Tracy T Batchelor
Journal:  Chin Clin Oncol       Date:  2017-06

2.  cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.

Authors:  Daniel J Brat; Kenneth Aldape; Howard Colman; Dominique Figrarella-Branger; Gregory N Fuller; Caterina Giannini; Eric C Holland; Robert B Jenkins; Bette Kleinschmidt-DeMasters; Takashi Komori; Johan M Kros; David N Louis; Catriona McLean; Arie Perry; Guido Reifenberger; Chitra Sarkar; Roger Stupp; Martin J van den Bent; Andreas von Deimling; Michael Weller
Journal:  Acta Neuropathol       Date:  2020-01-29       Impact factor: 17.088

3.  Cytosolic NADP+-dependent isocitrate dehydrogenase plays a key role in lipid metabolism.

Authors:  Ho-Jin Koh; Su-Min Lee; Byung-Gap Son; Soh-Hyun Lee; Zae Young Ryoo; Kyu-Tae Chang; Jeen-Woo Park; Dong-Chan Park; Byoung J Song; Richard L Veech; Hebok Song; Tae-Lin Huh
Journal:  J Biol Chem       Date:  2004-07-14       Impact factor: 5.157

4.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

5.  Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability.

Authors:  David R Wise; Patrick S Ward; Jessica E S Shay; Justin R Cross; Joshua J Gruber; Uma M Sachdeva; Jesse M Platt; Raymond G DeMatteo; M Celeste Simon; Craig B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-21       Impact factor: 12.779

Review 6.  Cancer-associated IDH mutations: biomarker and therapeutic opportunities.

Authors:  K E Yen; M A Bittinger; S M Su; V R Fantin
Journal:  Oncogene       Date:  2010-10-25       Impact factor: 8.756

7.  Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

Authors:  Daniel A Pollyea; Martin S Tallman; Stéphane de Botton; Hagop M Kantarjian; Robert Collins; Anthony S Stein; Mark G Frattini; Qiang Xu; Alessandra Tosolini; Wendy L See; Kyle J MacBeth; Samuel V Agresta; Eyal C Attar; Courtney D DiNardo; Eytan M Stein
Journal:  Leukemia       Date:  2019-04-09       Impact factor: 12.883

Review 8.  Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia.

Authors:  Rebecca A Myers; Scott Wirth; Sherry Williams; Patrick J Kiel
Journal:  J Adv Pract Oncol       Date:  2018-05-01

9.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

Review 10.  Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.

Authors:  Xiaoyan Liu; Yuping Gong
Journal:  Biomark Res       Date:  2019-10-22
View more
  15 in total

1.  Cryo-EM structures reveal multiple stages of bacterial outer membrane protein folding.

Authors:  Matthew Thomas Doyle; John R Jimah; Tyrone Dowdy; Shannon I Ohlemacher; Mioara Larion; Jenny E Hinshaw; Harris D Bernstein
Journal:  Cell       Date:  2022-03-15       Impact factor: 41.582

Review 2.  Isotope tracing in health and disease.

Authors:  Wentao Dong; Eshaan S Rawat; Gregory Stephanopoulos; Monther Abu-Remaileh
Journal:  Curr Opin Biotechnol       Date:  2022-06-20       Impact factor: 10.279

Review 3.  Advances in measuring cancer cell metabolism with subcellular resolution.

Authors:  Victor Ruiz-Rodado; Adrian Lita; Mioara Larion
Journal:  Nat Methods       Date:  2022-08-25       Impact factor: 47.990

Review 4.  Single cell metabolism: current and future trends.

Authors:  Ahmed Ali; Shawn Davidson; Ernest Fraenkel; Ian Gilmore; Thomas Hankemeier; Jennifer A Kirwan; Andrew N Lane; Ingela Lanekoff; Mioara Larion; Laura-Isobel McCall; Michael Murphy; Jonathan V Sweedler; Caigang Zhu
Journal:  Metabolomics       Date:  2022-10-01       Impact factor: 4.747

5.  Construction of a Risk Model to Predict the Prognosis and Immunotherapy of Low-Grade Glioma Ground on 7 Ferroptosis-Related Genes.

Authors:  Liwei Sun; Bing Li; Bin Wang; Jinduo Li; Jing Li
Journal:  Int J Gen Med       Date:  2022-05-05

6.  A Single-Organelle Optical Omics Platform for Cell Science and Biomarker Discovery.

Authors:  Artem Pliss; Andrey N Kuzmin; Adrian Lita; Rahul Kumar; Orieta Celiku; G Ekin Atilla-Gokcumen; Omer Gokcumen; Dhyan Chandra; Mioara Larion; Paras N Prasad
Journal:  Anal Chem       Date:  2021-05-28       Impact factor: 8.008

Review 7.  Unveiling Cancer Metabolism through Spontaneous and Coherent Raman Spectroscopy and Stable Isotope Probing.

Authors:  Jiabao Xu; Tong Yu; Christos E Zois; Ji-Xin Cheng; Yuguo Tang; Adrian L Harris; Wei E Huang
Journal:  Cancers (Basel)       Date:  2021-04-05       Impact factor: 6.639

8.  A mutation in transmembrane protein 135 impairs lipid metabolism in mouse eyecups.

Authors:  Michael Landowski; Vijesh J Bhute; Tetsuya Takimoto; Samuel Grindel; Pawan K Shahi; Bikash R Pattnaik; Sakae Ikeda; Akihiro Ikeda
Journal:  Sci Rep       Date:  2022-01-14       Impact factor: 4.996

9.  Nuclear FABP7 regulates cell proliferation of wild-type IDH1 glioma through caveolae formation.

Authors:  Yoshiteru Kagawa; Banlanjo Abdulaziz Umaru; Masayuki Kanamori; Ryo Zama; Subrata Kumar Shil; Hirofumi Miyazaki; Shuhei Kobayashi; Tunyanat Wannakul; Shuhan Yang; Teiji Tominaga; Yuji Owada
Journal:  Mol Oncol       Date:  2021-11-09       Impact factor: 6.603

Review 10.  From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.

Authors:  Xueyuan Sun; Sevin Turcan
Journal:  Cells       Date:  2021-05-17       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.